Kura Oncology's KOMZIFTI Hits $5.8M in First Full Quarter of Sales
Event summary
- KOMZIFTI generated $5.8M in net product revenue in its first full quarter of commercialization.
- Achieved >93% payer coverage across >12M lives, with 85 new patient starts and 157 total prescriptions.
- Multiple 2026 data readouts expected to support ziftomenib as a broadly combinable backbone across AML.
- $580.8M in cash and short-term investments, plus $180M in anticipated collaboration payments, expected to support AML program through 2028.
The big picture
Kura Oncology's strong first quarter for KOMZIFTI underscores the growing adoption of menin inhibitors in AML treatment. The company's strategy to position ziftomenib as a combinable backbone across the AML treatment continuum aligns with the industry's shift toward targeted therapies. With multiple data readouts expected in 2026 and a robust cash position, Kura is well-positioned to compete in the rapidly evolving oncology market.
What we're watching
- Commercial Momentum
- Whether Kura can sustain quarter-over-quarter revenue growth and establish leading class share in R/R NPM1-m AML.
- Clinical Data Readouts
- The pace at which upcoming data readouts for ziftomenib combinations in frontline and relapsed/refractory AML settings will impact market positioning.
- Pipeline Advancement
- How progress in darlifarnib and next-generation menin inhibitors will diversify Kura's revenue streams beyond AML.
Related topics